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Abstract
We aimed to study factors influencing outcomes of adults hospitalised for seasonal and pandemic 
influenza.
Individual-patient data from three Asian cohorts (Hong Kong, Singapore and Beijing; N=2649) 
were analysed. Adults hospitalised for laboratory-confirmed influenza (prospectively diagnosed) 
during 2008– 2011 were studied. The primary outcome measure was 30-day survival. Multivariate 
Cox regression models (time-fixed and time-dependent) were used.
Patients had high morbidity (respiratory/nonrespiratory complications in 68.4%, respiratory-failure 
in 48.6%, pneumonia in 40.8% and bacterial superinfections in 10.8%) and mortality (5.9% at 30 
days and 6.9% at 60 days). 75.2% received neuraminidase inhibitors (NAI) (73.8% received 
oseltamivir and 1.4% received peramivir/zanamivir; 44.5% of patients received NAI ⩽2 days and 
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65.5% ⩽5 days after onset of illness); 23.1% received systemic corticosteroids. There were fewer 
deaths among NAI-treated patients (5.3% versus 7.6%; p=0.032). NAI treatment was 
independently associated with survival (adjusted hazard ratio (HR) 0.28, 95% CI 0.19–0.43), 
adjusted for treatment-propensity score and patient characteristics. Superinfections increased 
(adjusted HR 2.18, 95% CI 1.52–3.11) and chronic statin use decreased (adjusted HR 0.44, 95% 
CI 0.23–0.84) death risks. Best survival was shown when treatment started within ⩽2 days 
(adjusted HR 0.20, 95% CI 0.12–0.32), but there was benefit with treatment within 3–5 days 
(adjusted HR0.35, 95% CI 0.21–0.58). Time-dependent analysis showed consistent results of NAI 
treatment (adjusted HR 0.39, 95% CI 0.27–0.57). Corticosteroids increased superinfection (9.7% 
versus 2.7%) and deaths when controlled for indications (adjusted HR 1.73, 95% CI 1.14–2.62). 
Early NAI treatment was associated with shorter length of stay in a subanalysis.
NAI treatment may improve survival of hospitalised influenza patients; benefit is greatest from, 
but not limited to, treatment started within 2 days of illness. Superinfections and corticosteroids 
increase mortality. Antiviral and non-antiviral management strategies should be considered.
Introduction
Influenza virus infections cause excessive hospitalisations and deaths of adults during 
seasonal peaks and pandemics. While predominantly older individuals are hospitalised for 
infections caused by seasonal influenza virus strains, younger, previously healthy adults may 
be hospitalised for H1N1pdm09 infections; at present, co-circulation of these viruses occurs 
worldwide [1]. Data from Asia are relatively limited but the estimated influenza disease 
burden is at least similar to that in western countries [2–4]. Adults hospitalised with 
influenza may suffer from a wide range of complications including pneumonia, respiratory 
failure, multiorgan dysfunction, secondary infections and exacerbation of underlying 
conditions, resulting in high mortality [3, 5, 6]. However, the most optimal management 
approach for these patients with complicated influenza has remained unclear, as data from 
randomised, placebo-controlled trials are lacking [3]. Many observational studies performed 
during the 2009 pandemic reported effectiveness of neuraminidase inhibitors (NAI) started 
within 2 days of illness, but most were limited by a small sample size, single-centre design 
and lack of adjustment for confounders; benefits of later treatment appeared inconsistent [7]. 
Besides antiviral agents, the relative impacts of other modifiable disease conditions and the 
use of concomitant medications on clinical outcomes are uncertain. In particular, bacterial 
superinfection has been suggested to play a major role in influenza-related deaths [3, 5], and 
corticosteroids may sometimes be administered in an attempt to improve oxygenation in 
severe respiratory failure [8]. In this study, we aimed to determine clinical factors that affect 
survival and illness duration in adult patients hospitalised for influenza. We conducted a 
large, multicentre cohort study in three cities in Asia; individual-patient data of laboratory-
confirmed seasonal or pandemic influenza virus infections were analysed in multivariate 
models. Such findings may optimise the overall management approach for severe influenza, 
leading to better clinical outcomes.
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Methods
Study design
A pooled analysis of individual-patient data from three Asian influenza cohorts (Hong Kong, 
Singapore and Beijing) was performed [5, 6, 9–12]. Adults aged >17 years hospitalised for 
laboratory-confirmed influenza A or B virus infections from January, 2008 to December, 
2011 (four calendar years) were included for analysis. Prince of Wales Hospital and Alice 
Ho Miu Ling Nethersole Hospital (Hong Kong), Tan Tock Seng Hospital (Singapore) and 
Beijing Chao-Yang Hospital (Beijing) are acute care, general hospitals serving urban 
populations. Case identification, laboratory diagnosis and management procedures at the 
individual study sites have been described previously [5, 6, 9–12]. Influenza cases were 
prospectively identified and diagnosed; patients presenting with symptoms of acute 
respiratory infection were admitted if they developed potentially serious medical 
complications (e.g. pneumonia or cardiovascular events), exacerbations of underlying 
conditions (e.g. chronic obstructive pulmonary disease (COPD) or asthma), or severe 
systemic/respiratory symptoms, which were unmanageable at home or as an outpatient. 
Following admission, patients were tested for influenza virus infections as part of hospital 
care and/or a surveillance programme. Virological diagnosis was established using reverse 
transcription PCR, and/or a combination of an immunofluorescence assay and virus culture. 
Chest radiography and bacterial culture of respiratory samples were routinely performed for 
patient management; blood cultures were performed when there were signs of sepsis. NAI 
(typically oral oseltamivir) were available for treatment at all sites and considered by the 
attending physicians based on clinical guidelines, which were evolving during the study 
period [3, 13, 14].
Data on patient characteristics, complications, treatments and outcomes, collected 
prospectively and retrospectively at individual sites [5, 6, 9–12], were extracted and 
combined into a central database using standardised definitions for variables (see later). A 
total of 2665 cases were collated; 16 were subsequent excluded because they did not fulfil 
the specified age criteria (N=2649: Hong Kong n=1893; Singapore n=408; Beijing n=348). 
All patient identifying information had been removed from the dataset and only anonymous 
data were used for analysis. This study was investigator-initiated and supported by a 
government research grant. Ethical approval for data collection was obtained from the 
institutional review boards of the participating sites.
Definition of variables and study outcomes
The primary outcome of the analysis was all-cause mortality within 30 days. The secondary 
outcomes were mortality within 60 days and duration of hospitalisation of survivors. 
“Comorbidity” was defined as the presence of one or more pre-existing, major medical 
conditions that are known risk factors for influenza-related complications (hypertension or 
hypercholesterolaemia alone were not considered high-risk conditions) (table 1) [5, 13]. 
“Pneumonia” was defined clinically and radiographically [5, 6]. “Bacterial superinfection” 
was defined as positive culture of a bacterial pathogen from a lower respiratory tract 
specimen (sputum, bronchial/tracheal aspirates or bronchoalveolar lavage) and/or blood 
samples collected during the acute illness, excluding results from other sites (e.g. urine, stool 
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or skin wound) [5, 6]. NAI treatment referred to the administration of oseltamivir, zanamivir 
or peramivir for one or more doses during the course of illness (table 1). Systemic 
corticosteroid use was defined as any intended therapeutic use of corticosteroids (e.g. 
methylprednisolone, prednisolone or hydrocortisone) via the parental or enteral routes 
during hospitalisation; replacement doses and inhalational treatment were excluded. Statin 
use referred to chronic use of a statin (for any length of time) prior to and at the time of 
hospitalisation.
Data analysis
Factors affecting patient survival were analysed. Chi-squared tests with continuity 
correction, Kaplan–Meier analysis and the log-rank test were used for univariate 
comparisons. Independent factors were determined using multivariate Cox regression 
models; age, sex, type/subtype of virus, NAI use, NAI treatment propensity score, bacterial 
superinfection, and systemic corticosteroid and statin use (all variables significant in the 
univariate comparisons) were included as covariates (model 1) [3, 5, 7, 8, 13]. The adjusted 
hazard ratios (HR) of the explanatory variables and their 95% confidence intervals were 
calculated; a HR <1 indicated a lower probability of death. To investigate whether time of 
treatment initiation would affect survival, NAI use was further categorised into those who 
started treatment within 0–2, 3–5 and >5 days from illness onset (model 2) [3, 5, 7]. In an 
attempt to address possible immortal time bias on treatment effectiveness, we also 
performed time-dependent Cox regressions with NAI initiation modelled as a time-
dependent covariate (with respect to the day of illness onset) [15, 16], with adjustment for 
the same variables (model 3). Furthermore, analysis was performed among patients with 
“pneumonia”, a defined, severe form of influenza complication (model 4) [5]. The 
propensity score for the likelihood of an individual patient to receive NAI treatment was 
calculated by a multivariate logistic regression method using the following variables [16, 
17]: 1) comorbidity (defined earlier); 2) requirement for assisted ventilation and/ or intensive 
care unit (ICU) admission (illness severity); 3) admission year (reflecting guideline changes 
preand post-pandemic); and 4) study site (possible differences in clinical practice) [3, 13]. 
Survival at 30 days and 60 days was analysed, because late deaths might occur due to 
complicated courses of illness and/or decompensation of the underlying conditions [6].
Factors affecting duration of hospitalisation of survivors were analysed using multivariate 
linear models, β-coefficients and 95% confidence intervals were calculated to provide 
adjusted estimates of differences in length of stay between the comparing factors. A 
subanalysis of patients who had respiratory failure, defined as hypoxaemia requiring 
supplemental oxygen support (i.e. among patients with more severe diseases) [5, 6], was 
performed.
Cox regressions and multivariate linear models were performed using the Proc PHREG and 
Proc GLM procedures in SAS, respectively (SAS version 9.3; SAS Institue Inc., Cary, NC, 
USA). Descriptive and univariate analyses were performed using the PASW Statistics 
version 18.0 (SPSS Inc., Chicago, IL, USA). All probabilities were two-tailed and a p-value 
of <0.05 was considered to indicate statistical significance.
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Results
Descriptions of cohort
Altogether data for 2649 hospitalised patients with laboratory-confirmed influenza were 
analysed. Their baseline characteristics, virological diagnoses, complications, treatments 
received and clinical outcomes are described in table 1. The numbers of patients enrolled in 
2008, 2009, 2010 and 2011 were 516 (19.5%), 1008 (38.1%), 660 (24.9%) and 465 (17.5%), 
respectively, including 2354 cases of influenza A and 295 cases influenza B (seasonal 
influenza A/B viruses 56.9%, influenza A(H1N1)pdm09 virus 36.3%). Lower respiratory 
tract specimens were used to establish the diagnosis in 9.1% of cases. The median age of the 
cohort was 63 years (interquartile range (IQR) 42–79 years) and 60.6% had one or more 
major comorbidities. The median time interval between illness onset and presentation to the 
hospitals was 2 days (IQR 1–3 days). Defined pulmonary and/or extrapulmonary 
complications were present in 68.4% of cases; clinicoradiological pneumonia was diagnosed 
in 40.8%. Culture-proven bacterial superinfections occurred in 10.8% of cases, of which 
4.3% were hospital-acquired (table 1). About half (48.6%) of the patients had respiratory 
failure requiring supplemental oxygen support; invasive/noninvasive ventilation or ICU 
admission was required for life-support in 11.5%. The crude all-cause mortality at 30 and 60 
days was5.9% (n=156) and 6.9% (n=183), respectively (mortality in NAI-treated versus -
untreated was 5.3% versus7.6% and 6.2% versus 9.0%, at 30 and 60 days respectively) 
(table 2). Cumulative proportions of death at 30, 40 and 50 days were 85%, 90% and 95%, 
respectively. For the survivors, the median hospital length-of-stay was 5 days (IQR 3–9 
days).
Overall, 1991 (75.2%) patients received NAI treatment, of whom 1956 (73.8%) were treated 
with either oseltamivir or an oseltamivir-containing regimen (other NAI: zanamivir or 
peramivir alone, n=35) (table 1). Proportions of NAI-treated patients in 2008, 2009, 2010 
and 2011 were 29.7%, 88.9%, 88.9% and 76.3%, respectively. Treatment was initiated 
within 0–2 days of illness in 44.5%, 3–5 days in 21.0% and >5 days in 9.3%. Systemic 
corticosteroids were given in 23.1%; a higher proportion of bacterial superinfection during 
the course of hospitalisation was found among the corticosteroid recipients (9.7% versus 
2.7%; p<0.001). There were 336 chronic statin users in this cohort; compared with the 
nonusers, they were significantly older (73±11 versus 58±23 years; p<0.001) and major 
comorbidities were more frequently present (94.3% versus 55.6%, p<0.001). Proportions 
with defined complications were similar(70.8% versus 68.0%; p=0.298).
Factors associated with mortality
In univariate analyses (table 2), older age, male sex, comorbidities, pneumonia, bacterial 
superinfections(17.5% versus 4.5%) and corticosteroid use (10.0% versus 4.7%) were 
significantly associated with mortality. Patients who received NAI treatment within 2 days of 
illness or within 5 days of illness, and those who were on chronic statin therapy (3.3% 
versus 6.3%) were shown to have lower risks of death at 30 days. Results were similar for 
death at 60 days. Kaplan–Meier curves comparing survival with regard to NAI treatment 
status, treatment initiation time, corticosteroids and statin use are shown in figure 1a–d.
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Results of multivariate Cox regression analyses (censored at 30 days) are shown in table 3. 
In model 1, NAI treatment was found to be an independent factor associated with improved 
survival versus no treatment (adjusted HR 0.28, 95% CI 0.19–0.43; p<0.001), adjusted for 
propensity score, patient characteristics and virus type/subtype. Bacterial superinfection 
(adjusted HR 2.18, 95% CI 1.52–3.11; p<0.001) and chronic statin use (adjusted HR 0.44, 
95% CI 0.23–0.84; p=0.013) were associated with increased and decreased death risks, 
respectively. In model 2, early NAI treatment within 2 days of illness was associated with 
the highest chance of survival (adjusted HR 0.20, 95% CI 0.12–0.32; p<0.001), but 
improved survival was also observed with treatment started within 3–5 days, compared with 
no treatment (adjusted HR 0.35, 95% CI 0.21–0.58; p<0.001). In model 3, NAI initiation, 
modelled as a time-dependent covariate, was significantly associated with survival (adjusted 
HR 0.39, 95% CI 0.27–0.57; p<0.001), adjusted for the same confounders. Model 4, the 
analysis of complicated infections with pneumonia, showed similar results. The progressive 
increase in the hazard ratios with each day of delay in starting NAI treatment after illness 
onset is shown in supplementary figure S1.
Survival analyses censored at 60 days showed consistent results; NAI treatment, bacterial 
superinfection and statin use were the significant variables (supplementary table S1). We 
further examined the impact of systemic corticosteroid use in a post hoc analysis excluding 
patients with known indications for the treatment of acute airway disease exacerbations. 
Corticosteroid administration was shown to be significantly associated with increased death 
risks (adjusted HR 1.73, 95% CI 1.14–2.62; p=0.010) (supplementary table S2 and table 2).
Factors associated with duration of hospitalization
Analyses of duration of hospitalisation data are shown in table 4. For all survivors, it was 
found that older age, bacterial superinfection and corticosteroid use were significantly 
associated with length of stay, whereas an insignificant trend of association was shown for 
NAI treatment. In a subanalysis of patients with respiratory failure, however, significantly 
longer length of stay was observed in patients who did not receive NAI treatment within 5 
days of illness (p=0.023). Those who received early treatment within 2 days of illness had 
the shortest length of stay (table 4).
Discussion
In this large, multicentre cohort study, we show that adults hospitalised for seasonal or 
pandemic influenza have high morbidity and mortality. Apart from the conventional risk 
factors such as old age and comorbidity, we found that NAI treatment, secondary infections, 
systemic corticosteroid and statin use may affect clinical outcomes. These findings have 
important implications for patient care.
Our results are consistent with other cohort studies and recent meta-analyses which showed 
that early NAI treatment is associated with improved survival in H1N1pdm09 influenza 
patients [7, 16]. In this analysis, we included both seasonal and pandemic virus subtypes, 
and carefully controlled for important confounders including patient characteristics, disease 
severity, propensity to receive NAI treatment and possible immortal time bias, with the aim 
of providing a more accurate estimate on the effectiveness of antiviral intervention on 
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outcomes. Effects on survival, as well as illness duration, were studied. Overall, NAI 
treatment was found to be associated with a reduced risk of death by ~72% (adjusted HR 
0.28, 95% CI 0.19–0.43) in the time-fixed, and 61% (adjusted HR 0.39, 95% CI 0.27–0.57) 
in the time-dependent analyses; significant results were also observed in cases complicated 
by pneumonia (table 3). Notably, the majority (58%) of our treated patients had received 
NAI within 2 days of illness and they were shown to have the best chance of survival. 
Benefits were also found with later treatment initiation, but the magnitude was smaller, and 
decreased rapidly with longer time delays (fig. 1b and supplementary fig S1). In hospitalised 
influenza patients, a greater therapeutic time window is expected as viral replication is 
usually more prolonged; however, if the disease has progressed to an advanced stage, 
antivirals alone may not reverse the course because of extensive inflammation-mediated 
tissue damage [8, 18–20]. Along the continuum, findings of effectiveness appear to be most 
consistent with treatment started within 5 days [21–24]; however, a small benefit with later 
treatments cannot be ruled out. We also found evidence that early NAI treatment may 
shorten length of stay when patients with more severe diseases were analysed (see later) [6, 
18, 25]. Our data support the recommendation to start NAI as soon as possible in all patients 
hospitalised with confirmed or suspected influenza, including those who present after 2 days 
following onset [13]. We noted that although the time to presentation was ⩽2 days in 50% 
and ⩽5 days in 85% of cases, considerably fewer were given antivirals and, as in western 
countries, there was a drop in antiviral use after the 2009 pandemic [26]. Strategies to 
improve rapid diagnosis, accessibility and use of antivirals are urgently required [3, 4, 27].
Bacterial superinfections were documented in ~11% of cases (>4% hospital acquired), and 
were associated with a two-fold increase in death risk and an extended period of 
hospitalisation. The true incidence could be even higher as only culture-proven cases were 
reported [5]. It is increasingly recognised that complex interactions exist between the co-
infecting pathogens and the host, leading to disruption of physical barriers, outgrowth of 
pathogens and potentiated inflammation-mediated injury [28]. As such, prompt detection of 
bacterial superinfection and appropriate antibiotic coverage are advisable [3, 27]. Besides 
the usual pathogens Streptococcus pneumoniae and Staphylococcus aureus, drug-resistant 
Gram-negative bacteria are a particular concern in our region [6, 12]. Measures to prevent 
nosocomial infections, particularly ventilator-associated pneumonia, should be implemented 
[29]. We reported more superinfections (9.7% versus 2.7%) and deaths (10.0% versus 4.7%) 
among patients receiving systemic corticosteroids, the death risk was significant (adjusted 
HR 1.7, 95% CI 1.1–2.6) after controlling for indications and confounders (table 2 and 
supplementary table S2) [30–32]. Available evidence indicates that corticosteroids do not 
effectively suppress inflammation in influenza but further impair host defence resulting in 
delayed viral clearance and bacterial/ fungal sepsis [8, 18, 27, 30–32]. Although selection 
bias (“treating the sickest”) cannot be eliminated, our results suggest that corticosteroids 
should not be administered routinely for the treatment of influenza pneumonia. In patients 
with established indications, such as therapy for acute airway disease exacerbations, it may 
be prudent to monitor for viral clearance and minimise corticosteroid exposure [8, 18, 27].
Numerous reports have described benefits of statin use in sepsis, pneumonia and COPD 
exacerbation, which have been attributed to their anti-inflammatory properties [8, 33, 34]. 
Data on influenza are limited, and recently, an association with lower mortality risk 
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(adjusted for vaccination status) in hospitalised influenza patients has been reported [33, 35]. 
We observed fewer deaths among the chronic statin users (3.3% versus 6.3%), despite their 
older age and the presence of major comorbidities (not including hypercholesterolaemia), 
which is not readily explainable by the “healthy user bias” [36]. Recent trials on acute statin 
administration in non-influenza diseases (e.g. sepsis or acute respiratory distress syndrome) 
have shown negative results [37], but continuation of pre-existing therapy seems beneficial 
[38]. Given these observations, further studies on the immunological/metabolic effects of 
prior, chronic statin use in influenza patients is still warranted, which may provide insights 
into pathogenesis and adjunctive therapy research [8, 33, 36, 38, 39].
The strengths of our study include a large sample size, multicentre design and virological 
confirmation of cases. Important confounders, including the propensity to receive antiviral 
treatment, have been carefully controlled. Results from univariate and multivariate analyses 
are consistent, and both time-fixed and time-dependent regressions were performed to 
provide estimates of risks [40]. Limitations pertaining to observational studies are 
unavoidable but it is unlikely that selection bias, such as omitting antivirals for milder 
infections, could explain the mortality differences. Early discharge of mild, untreated 
patients is possible; therefore, treatment impact on length of stay was further examined 
among the severe cases. Since only a small proportion of cases (<6%) was infected with the 
seasonal A(H1N1) virus (~60% oseltamivir resistant in 2008–2009) [6, 41], and most had 
either received zanamivir or remained untreated (table 1), the conclusions should be 
unaffected. We are unable to study the impact of influenza vaccination due to incomplete 
data, but vaccination coverage in Asian populations is known to be very low and the 
monovalent A(H1N1)pdm09 vaccine was largely unavailable during the 2009 pandemic [5, 
6, 9, 11, 42, 43]. Given the reported high prevalence of the IFITM3 CC-genotype (associated 
with influenza progression) in Asian populations [44], future studies may need to consider 
genetic/ethnicity factors when analysing disease outcomes.
In conclusion, our data suggest that NAI treatment may improve survival of hospitalised 
influenza patients. The benefit is greatest with, but not limited to, treatment started within 2 
days of illness. Secondary infections and corticosteroids may increase death risks. In view of 
these findings, the overall management approach will need to consider both antiviral (e.g. 
early diagnosis and treatment, and empirical treatment of suspect cases) and non-antiviral 
(e.g. treatment and prevention of superinfections, avoidance of corticosteroids or other 
immunosuppressants) strategies to optimise patient outcomes.
Supplementary Material
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FIGURE 1. 
Kaplan–Meier survival curves of adult patients hospitalised for confirmed influenza virus 
infections, censored at 30 days. Survival according to a) neuraminidase inhibitors (NAI) 
treatment status (log-rank test p=0.002), b) NAI initiation time (log-rank test p<0.001), c) 
systemic steroid use (log-rank test p=0.038) and d) chronic statin use (log-rank test 
p=0.013).
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TABLE 1
Characteristics, complications, treatments and outcomes of 2649 adults hospitalised with virologically 
confirmed influenza virus infections
Study site
 Hong Kong 1893 [71.5]
 Singapore 408 [15.4]
 Beijing 348 [13.1]
Year of diagnosis
 2008 516 [19.5]
 2009 1008 [38.1]
 2010 660 [24.9]
 2011 465 [17.5]
Baseline characteristics
 Age years 63.0 [42.0–79.0]
  ⩽20 102 [3.9]
  21–40 525 [19.8]
  41–60 606 [22.9]
  61–80 833 [31.4]
  >80 583 [22.0]
 Male sex 1370 [51.7]
 Any comorbidity# 1604 [60.6]
  Major systemic comorbidity 1318 [49.8]
  Chronic lung disease 561 [21.2]
  Influenza vaccination received¶ 207 [17.5]
Virological diagnosis
 Seasonal influenza A+ 1212 [45.8]
 Pandemic influenza A H1N1pdm09 961 [36.3]
 Influenza A, subtyping data unavailable 181 [6.8]
 Influenza B 295 [11.1]
 Upper respiratory tract samples 2131 [90.8]
 Lower respiratory tract samples§ 213 [9.1]
 PCR positivity rate 1335/1465 [91.1]
 Antigen test positivity rateƒ 1528/1901 [80.4]
 Culture positivity rate 1543/1793 [86.1]
Complications
 Any complications## 1811 [68.4]
 Respiratory complications 1479 [55.8]
  Pneumonia 1081 [40.8]
  Airway disease 510 [19.3]
 Extrapulmonary complications 410 [15.5]
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  Cardiovascular 193 [7.3]
  Neurological 109 [4.1]
  Gastrointestinal 134 [5.1]
 Bacterial superinfection¶¶ 286 [10.8]
  At presentation 185 [7.0]
  Hospital acquired 114 [4.3]
Treatments and outcomes
 Antiviral treatment, any NAI++ 1991 [75.2]
  Oseltamivir 1956 [73.8]
 Symptom onset-to-treatment interval days 2 [1–4]
  Started within 2 days++ 1160 [44.5]
  Started within 5 days 1706 [65.5]
 Antibacterials¶¶ 2282 [88.1]
 Systemic corticosteroids 610 [23.1]
 Statin use 336 [12.7]
 Supplemental oxygen§§ 1249 [48.6]
 Ventilatory support and/or ICU admission§§ 305 [11.5]
 Death at 30 days 156 [5.9]
 Death at 60 days 183 [6.9]
 Time to death days 8 [3–17]
 Length of stay of survivors days 5 [3–9]
Data are presented as n (%), n/N (%) or median (interquartile range), unless otherwise stated. Other patient characteristics: ethnic Chinese 92.8%; 
nursing home residents 13.9% (344 out of 2478); obesity 2.2% (49 out of 2253); pregnant women 10.7% (44 out of 411 reproductive age females). 
NAI: neuraminidase inhibitors; ICU: intensive care unit.
#:
major systemic comorbidity [4, 12] defined as congestive heart failure, cerebrovascular, neoplastic, or chronic liver or renal diseases, diabetes 
mellitus, chronic cardiovascular, autoimmune or neurological diseases, or immunosuppression (not hypertension or hypercholesterolaemia alone); 
chronic lung diseases were defined as chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis and pulmonary fibrosis.
¶:data on influenza vaccine status available in 1181 patients only.
+:
most cases were influenza A/H3N2; only 150 seasonal influenza A/H1N1 cases were confirmed during 2008 and early 2009, of which 73 did not 
receive oseltamivir treatment; the remainder received either zanamivir, or oseltamivir plus amantadine.
§:diagnostic specimen data were available in 2346 cases; lower respiratory tract samples included sputum, endotracheal aspirates and 
bronchoalveolar lavage, as diagnostic specimens, upper respiratory samples included nasopharyngeal aspirates and nasal/throat swabs.
ƒ:
antigen tests (Hong Kong only); 1784 out of 1901 (93.8%) were immunofluorescence assay, positivity rate for H1N1pdm09 virus was 64.2%.
##:
complications [4, 5, 12] were categorised as respiratory (clinicoradiographical pneumonia, acute bronchitis, acute exacerbations of asthma or 
COPD), extrapulmonary (cardiovascular (e.g. acute coronary syndrome, decompensated heart failure, arrhythmia or myocarditis), neurological (e.g. 
encephalopathy, confusion or delirium, seizure, stroke or transient ischaemic attack), gastrointestinal (e.g. severe vomiting, diarrhoea, abdominal 
pain, gastrointestinal bleeding or liver derangement)) or other (metabolic derangement, renal failure, sepsis syndrome, syncope, etc.).
¶¶:bacterial superinfection [4, 5] was evidenced by positive culture of a bacterial pathogen from respiratory (sputum or bronchial/ tracheal 
aspirates) and/or blood samples; infections with onset >2 days after admission were considered hospital acquired (concurrent Aspergillus 
infections, n=7); antibacterial data unknown (n=121).
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++:
antiviral treatment included oseltamivir use (n=1956), inhalational zanamivir alone (n=30), peramivir alone (n=5), oseltamivir and peramivir 
(n=5), oseltamivir and zanamivir (n=18), oseltamivir and amantadine (n=35), no antiviral (n=658); symptom onset date unknown (n=44), treatment 
duration >5 days (21.6%).
§§:data on supplemental oxygen use unknown (n=78); ventilatory support included invasive or noninvasive ventilatory support.
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TABLE 2
Factors associated with death at 30 and 60 days
Outcome at 30 days Outcome at 60 days
Died Survived p-value Died Survived p-value
Baseline characteristics
 Subjects n 156 2493 183 2466
 Age years median [IQR] 74 [52–86] 63 [41–79] <0.001 73 [54–86] 62 [41–79] <0.001
 Male sex 97 [62.2] 1273 [51.1] 0.007 115 [62.8] 1255 [50.9] 0.002
 Any comorbidity 118 [75.6] 1486 [59.6] <0.001 141 [77.0] 1463 [59.3] <0.001
Virus strains
 H1N1pdm09 versus seasonal viruses# 62 [40.5] 899 [38.8] 0.678 73 [40.8] 888 [38.8] 0.599
 Influenza A versus B 138 [88.5] 2216 [88.9] 0.869 162 [88.5] 2192 [88.9] 0.880
Complications
 Pneumonia 137 [87.8] 944 [37.9] <0.001 155 [84.7] 926 [37.6] <0.001
 Cardiovascular event 20 [12.8] 173 [6.9] 0.006 27 [14.8] 166 [6.7] <0.001
 Bacterial superinfection 50 [32.1] 236 [9.5] <0.001 55 [30.1] 231 [9.4] <0.001
Treatments
 Antiviral treatment, any NAI 106 [67.9] 1885 [75.6] 0.032 124 [67.8] 1867 [75.7] 0.016
 Started within 2 days¶ 42 [28.8] 1118 [45.5] <0.001 52 [30.1] 1108 [45.6] <0.001
 Started within 5 days¶ 72 [49.3] 1634 [66.4] <0.001 86 [49.7] 1620 [66.6] <0.001
 Systemic corticosteroids+ 60 [38.5] 540 [21.7] <0.001 70 [38.3] 530 [21.5] <0.001
 Statin use+ 11 [7.1] 325 [13.0] 0.029 16 [8.7] 320 [13.0] 0.097
Data are presented as n (%), unless otherwise stated. IQR: interquartile range; NAI: neuraminidase inhibitors.
#:
seasonal influenza viruses included A/H3N2, A/H1N1, B (subtyping data unavailable n=181); crude mortality was higher with H1N1pdm09 
infection among patients aged <65 years (p=0.002).
¶:NAI treatment started within 2 days (versus >2 days and none) and 5 days (versus >5 days and none) from illness onset. Mortality at 30 days by 
NAI initiation time intervals for the whole cohort: NAI within 0–2 days (3.6%), 3–5 days (5.5%), >5 days (10.0%), none(7.6%); and for the 
pneumonia subgroup: NAI within 0–2 days (8.5%), 3–5 days (10.7%), >5 days (14.0%), none (18.9%); both p=0.001.
+:
corticosteroid use and mortality at 30 days in the pneumonia subgroup: 19.1% versus 10.6% (p<0.001), airway disease exacerbations subgroup: 
6.0% versus 7.2% (p=0.683); statin use and mortality in the pneumonia subgroup: 9.6% versus 13.0% (p=0.289), airway disease exacerbations 
subgroup 0% versus 7.2% (p=0.056).
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TABLE 3
Adjusted hazard ratios of explanatory variables associated with death, as shown in multivariate Cox regression 
models (censored at 30 days)
Adjusted hazard ratio (95% CI) p-value
Model 1#
 Age per 20 years 1.13 [0.95–1.36] 0.170
 Male sex 1.38 [1.00–1.92] 0.053
 H1N1pdm09 1.35 [0.90–2.02] 0.142
 Bacterial superinfection 2.18 [1.52–3.11] <0.001
 NAI treatment 0.28 [0.19–0.43] <0.001
 Statin use 0.44 [0.23–0.84] 0.013
 Systemic corticosteroids 1.11 [0.79–1.56] 0.554
Model 2¶
 Age per 20 years 1.21 [1.00–1.46] 0.050
 Male sex 1.48 [1.05–2.09] 0.024
 H1N1pdm09 1.15 [0.74–1.79] 0.538
 Bacterial superinfection 2.14 [1.48–3.10] <0.001
 NAI treatment
  0–2 days 0.20 [0.12–0.32] <0.001
  3–5 days 0.35 [0.21–0.58] <0.001
  >5 days 0.49 [0.27–0.88] 0.017
  None
 Statin use 0.49 [0.26–0.94] 0.032
 Systemic corticosteroids 1.04 [0.73–1.48] 0.839
Model 3+
 Age per 20 years 1.15 [0.95–1.38] 0.148
 Male sex 1.34 [0.96–1.86] 0.083
 H1N1pdm09 1.11 [0.75–1.65] 0.611
 Bacterial superinfection 2.18 [1.53–3.11] <0.001
 NAI treatment§ 0.39 [0.27–0.57] <0.001
 Statin use 0.42 [0.22–0.81] 0.009
 Systemic corticosteroids 1.09 [0.77–1.53] 0.629
Model 4ƒ
 Age per 20 years 1.01 [0.82–1.24] 0.935
 Male sex 1.16 [0.82–1.65] 0.392
 H1N1pdm09 0.65 [0.42–1.02] 0.062
 Bacterial superinfection 1.50 [1.03–2.19] 0.034
 NAI treatment§ 0.39 [0.26–0.59] <0.001
 Statin use 0.59 [0.30–1.13] 0.112
 Systemic corticosteroids 1.12 [0.78–1.61] 0.553
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In all models, neuraminidase inhibitors (NAI) treatment propensity score was included as a covariate (see methods), and had a p-value <0.05. An 
adjusted hazard ratio <1 indicated a lower probability of death.
#:
model 1 was adjusted for NAI treatment, bacterial superinfection, statin and corticosteroid use (yes versus no) and H1N1pdm09 (versus seasonal 
influenza A/B viruses).
¶:
model 2 was adjusted for NAI treatment; “none” was the reference group.
+:
time-dependent Cox regression.
§:
models 3 and 4 were time-dependent Cox regressions; NAI treatment initiation with respect to day of illness onset was analysed as a time-
dependent covariate (versus none).
ƒ:pneumonia subgroup.
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TABLE 4
Independent factors associated with hospital length of stay, as shown in multivariate linear models
β (95% CI) p-value
All survivors
 Age per 20 years 1.72 [1.30–2.14] <0.001
 H1N1pdm09# 2.20 [1.28–3.11] <0.001
 Bacterial superinfection¶ 7.63 [6.31–8.94] <0.001
 NAI started within 5 days+ −0.74 [−1.58–0.10] 0.084
 Systemic corticosteroids¶ 3.15 [2.19–4.10] <0.001
Respiratory failure subgroup
 Age per 20 years 1.56 [0.62–2.50] 0.001
 H1N1pdm09# 1.75 [−0.07–3.56] 0.059
 Bacterial superinfection¶ 9.83 [7.73–11.94] <0.001
 NAI started within 5 days+,§ −1.97 [–3.68–−0.27] 0.023
 Systemic corticosteroids¶ 1.54 [−0.02–3.11] 0.054
Data are presented as adjusted estimates (β) and 95% confidence intervals of the differences in length of stay (LOS) (days). Comorbidity, sex and 
statin use were adjusted in all models, which showed insignificant results. NAI: neuraminidase inhibitors.
#:
H1N1pdm09 versus seasonal influenza A/B viruses.
¶:yes versus no.
+:NAI treatment started within 5 days of illness versus no or later treatment.
§:
estimated differences in LOS (β) with NAI started within 0–2 days versus none (β −2.08, 95% CI −4.36–0.20), 3–5 days versus none (β −1.08, 
95% CI −3.71–1.54) and >5 days versus none (β 0.50, 95% CI −2.59–3.60). Respiratory failure was present at the time of NAI initiation in nearly 
all cases. A supplementary analysis using the time-dependent Cox regression method showed a significant association between NAI use and 
hospital discharge (adjusted hazard ratio 1.22, 95% CI 1.10–1.34, p<0.001; data not shown).
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